Preclinical Capabilities

Cell Therapy/Immuno-Oncology Preclinical Models

Trusted immune-oncology models for optimal CAR-T study design

TD2 is your trusted, experienced team when it comes to running preclinical Adoptive Cell Transfer Therapy studies. Our extensive knowledge of CAR-T in both solid and hematologic tumors enables optimal study design and rapid study initiation.

Not only can we execute your preclinical studies, but we provide a consultative approach to ensure best results and continuity with a clinical and regulatory strategy. Having performed hundreds of studies and strong experience with CAR T-cell handling and processing, we have the specialized oncology knowledge to design and execute your preclinical program in support of your clinical and regulatory goals.

TD2 can begin with cryopreserved or fresh CAR T-cells. We use fluorescent-based counting methods rather than manual dye counting to learn more about the viability of the CAR T-cells. Fluorescent counting helps to more accurately determine cell count and viability.

Cell Therapy Capabilities of 400+ Cell line derived xenograft (CDX) models include:

• Optical imaging (Bioluminescence and Fluorescence)
• Orthotopic and surgical
• IP Dissemination
• IV Dissemination
• Hematological
• Biodistribution
• Non-GLP Toxicity